Halozyme Therapeutics (HALO) News Today $46.96 -0.36 (-0.76%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target at $61.11December 22 at 2:36 AM | americanbankingnews.comTidal Investments LLC Buys 14,947 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Tidal Investments LLC lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 265.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,576 shares of the biopharmaceutiDecember 20 at 4:51 AM | marketbeat.comSanctuary Advisors LLC Has $2.12 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Sanctuary Advisors LLC increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 80.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,039 shares of the biopharmaceutical compaDecember 19 at 4:55 AM | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten analysts that are covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and six have assiDecember 19 at 2:26 AM | marketbeat.comPositive Outlook for Halozyme: Buy Rating Affirmed Despite FDA Setback, Strong ENHANZE Platform Drives Growth PotentialDecember 18, 2024 | markets.businessinsider.comHalozyme Therapeutics' (HALO) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday.December 18, 2024 | marketbeat.comWellington Management Group LLP Has $3.73 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Wellington Management Group LLP reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 83.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 65,157 shares of the biopharmaceutical company's stock aftDecember 18, 2024 | marketbeat.comIf You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth NowDecember 16, 2024 | msn.comGeode Capital Management LLC Increases Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Geode Capital Management LLC raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 1.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,060,131 shares of the biopharmaceuticaDecember 16, 2024 | marketbeat.comRetirement Systems of Alabama Has $22.28 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Retirement Systems of Alabama raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 23.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 389,268 shares of the biopharmaceutical comDecember 15, 2024 | marketbeat.comWorld Investment Advisors LLC Acquires Shares of 57,526 Halozyme Therapeutics, Inc. (NASDAQ:HALO)World Investment Advisors LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the third quarter, according to its most recent filing with the SEC. The fund bought 57,526 shares of the biopharmaceutical company's stock, valued at approximately $3,293December 14, 2024 | marketbeat.comZacks Research Issues Optimistic Forecast for HALO EarningsHalozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Equities research analysts at Zacks Research upped their FY2025 earnings per share estimates for Halozyme Therapeutics in a research note issued on Tuesday, December 10th. Zacks Research analyst R. Department now anticipates that the biophDecember 13, 2024 | marketbeat.comZacks Research Issues Optimistic Estimate for HALO EarningsDecember 13, 2024 | americanbankingnews.comZacks Research Issues Positive Forecast for HALO EarningsHalozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Stock analysts at Zacks Research increased their Q1 2025 EPS estimates for Halozyme Therapeutics in a research report issued to clients and investors on Tuesday, December 10th. Zacks Research analyst R. Department now expects that the biopDecember 12, 2024 | marketbeat.comHodges Capital Management Inc. Lowers Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Hodges Capital Management Inc. trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 5.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 320,544 shares of the biopharmaceuDecember 8, 2024 | marketbeat.comPier Capital LLC Lowers Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Pier Capital LLC lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 34.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 144,850 shares of the biopharmaceutical companyDecember 8, 2024 | marketbeat.comCastleark Management LLC Takes $3.99 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Castleark Management LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 69,720 shares of the biopharmaceutical companDecember 8, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Janus Henderson Group PLCJanus Henderson Group PLC increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 6.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 545,173 shares of the biopharmaceutical comDecember 7, 2024 | marketbeat.comErste Asset Management GmbH Takes $2.72 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Erste Asset Management GmbH purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 47,800 shares of the biopharmaceutical compDecember 3, 2024 | marketbeat.comCaisse DE Depot ET Placement DU Quebec Takes $5.38 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Caisse DE Depot ET Placement DU Quebec bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 94,009 shares of the biopharmaceutical company'sDecember 3, 2024 | marketbeat.comBridgewater Associates LP Sells 21,706 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Bridgewater Associates LP lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 65.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,515 shares of the biopharmDecember 3, 2024 | marketbeat.comEdgestream Partners L.P. Purchases 46,352 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Edgestream Partners L.P. lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 116.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 86,001 shares of the biopharmaceuticDecember 1, 2024 | marketbeat.comHantz Financial Services Inc. Buys New Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Hantz Financial Services Inc. purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 161,772 shares of the biopharmaceutical company'sNovember 30, 2024 | marketbeat.comCreativeOne Wealth LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)CreativeOne Wealth LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 18,089 shares of the biopharmaceutical company's stock, valued at approximately $1,035,000. ONovember 30, 2024 | marketbeat.comTownsquare Capital LLC Purchases 44,044 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Townsquare Capital LLC boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 74.4% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 103,223 shares of the biopharmaceutical company's stock after purchasing an additNovember 29, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Glenmede Trust Co. NAGlenmede Trust Co. NA lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 487,131 shares of the biopharmaceutical comNovember 28, 2024 | marketbeat.comFisher Asset Management LLC Has $18.55 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Fisher Asset Management LLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 6.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 324,005 shares of the biopharmaceutical compaNovember 28, 2024 | marketbeat.com32,942 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by RPg Family Wealth Advisory LLCRPg Family Wealth Advisory LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 32,942 shares of the biopharmaceutical company's stock, valued at apNovember 27, 2024 | marketbeat.comHalozyme to Present at Upcoming Investor ConferencesNovember 27, 2024 | prnewswire.comSwedbank AB Decreases Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Swedbank AB reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 4.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 318,362 shares of the biopharmaceutical company's stock afNovember 27, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Trims Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Charles Schwab Investment Management Inc. lowered its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.8% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,773,397 shares of the biopharmaceutical compaNovember 27, 2024 | marketbeat.comStrategic Focus and ENHANZE Platform Drive Buy Rating for HalozymeNovember 26, 2024 | markets.businessinsider.comHalozyme: Growth Amid Uncertainty After Failed Acquisition (Rating Downgrade)November 26, 2024 | seekingalpha.comIntech Investment Management LLC Has $3.22 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Intech Investment Management LLC boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 147.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 56,305 shares of the biopharmaceutical compNovember 24, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and six have given a buy ratingNovember 24, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Sees Strong Trading Volume - Time to Buy?Halozyme Therapeutics (NASDAQ:HALO) Sees Strong Trading Volume - Here's WhyNovember 22, 2024 | marketbeat.comHalozyme Therapeutics, Inc.: Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in DiscussionsNovember 22, 2024 | finanznachrichten.deHalozyme shares jump 12% as it scraps $2.1 bln Evotec dealNovember 22, 2024 | finance.yahoo.comHalozyme gains after withdrawing Evotec bidNovember 22, 2024 | msn.comHalozyme withdraws $2.1 bln buyout offer for EvotecNovember 22, 2024 | reuters.comHalozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in DiscussionsNovember 22, 2024 | prnewswire.com33,183 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Bought by B. Metzler seel. Sohn & Co. Holding AGB. Metzler seel. Sohn & Co. Holding AG acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 33,183 shares of the biopharmaceutNovember 22, 2024 | marketbeat.comThrivent Financial for Lutherans Lowers Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Thrivent Financial for Lutherans lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 75.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 233,016November 22, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Natixis Advisors LLCNatixis Advisors LLC grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 86.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 121,560 shares of the biopharmaceuticNovember 22, 2024 | marketbeat.comAurora Investment Counsel Sells 12,753 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Aurora Investment Counsel reduced its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,350 shares of the biopharmaceuticaNovember 21, 2024 | marketbeat.comSegall Bryant & Hamill LLC Has $20.33 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Segall Bryant & Hamill LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 16.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 355,176 sharesNovember 21, 2024 | marketbeat.comHalozyme’s Competitive Edge: Butler’s Buy Rating Amid Emerging CompetitorsNovember 21, 2024 | markets.businessinsider.comHalozyme’s Transformative Acquisition of Evotec: A Strategic Move for Growth and Market ExpansionNovember 21, 2024 | markets.businessinsider.comHalozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec DealNovember 19, 2024 | seekingalpha.comHalozyme Therapeutics (NASDAQ:HALO) Shares Gap Up - Here's WhyHalozyme Therapeutics (NASDAQ:HALO) Shares Gap Up - Here's What HappenedNovember 19, 2024 | marketbeat.com Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast. Click here for the ticker >>> HALO Media Mentions By Week HALO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HALO News Sentiment▼1.100.60▲Average Medical News Sentiment HALO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HALO Articles This Week▼118▲HALO Articles Average Week Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BIIB News Today UTHR News Today NBIX News Today INCY News Today BMRN News Today EXAS News Today EXEL News Today RGEN News Today MDGL News Today IONS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HALO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
